Cardiorenal-focused CorMedix prices IPO
This article was originally published in Scrip
Executive Summary
CorMedix, a New Jersey-based company that has a strategy of in-licensing technology to address the inter-related problems of cardiovascular and renal disease, has priced an initial public offering on the New York Stock Exchange's Amex exchange.